Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2005. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically correcting an administrative error regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan adjustments.
Key transactional values noted:
- Ordinary Share price: GBP 13.28
- Ordinary Share ADR price: $50.03
Material Changes
The filing corrects a previous announcement (RNS Announcement 7589O released on July 11, 2005) concerning the notional re-investment of dividends paid on July 7, 2005. An administrative error in the calculation of these re-investments was identified, necessitating a revision to the notional interests in Ordinary Shares and ADRs for specific plan participants.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary contingency noted is the correction of the administrative error, which resulted in updated notional share counts for the listed directors and managers. Dividends accrued on these notional shares will be paid out based on the percentage of holdings that vest after the relevant three-year measurement period.
Investor Verification Points
- Verify the corrected notional share and ADR counts for the listed directors against the July 11, 2005 announcement.
- Confirm the vesting schedule and payout mechanics for the Performance Share Plan dividends.
- Note that this filing replaces the previous RNS Announcement 7589O.